The pharmaceutical industry is accelerating its competition for patient-tailored prescriptions by refining dosages and formulations. The structure of treatment prescriptions is becoming increasingly detailed.
According to industry sources on June 7, competition among pharmaceutical companies to offer low-dose options is intensifying, particularly for treatments addressing hyperlipidemia, hypertension, and Alzheimer's disease, which are gaining attention in an aging society.
JW Pharmaceutical has launched a low-dose product for hyperlipidemia treatment, 'Rivarojet 1/10mg,' this month. Rivarojet is the first dual-combination improved new drug in South Korea that combines pitavastatin, a treatment for hyperlipidemia, with ezetimibe. The newly introduced Rivarojet 1/10mg combines 1mg of pitavastatin with 10mg of ezetimibe, expanding the dosage options available to patients while considering their LDL-C levels and treatment goals, alongside the existing 2/10mg and 4/10mg lineups.
The addition of low-dose products allows for more precise dosage adjustments from the start of treatment, thereby broadening patient-specific treatment options. The medical community can now provide more refined prescriptions by considering LDL-C levels, treatment goals, and the risk of side effects.
Earlier, Daewoong Pharmaceutical also released a combination drug for hyperlipidemia, 'Barojet Tablet.' Barojet Tablet is a low-dose combination of 1mg of pitavastatin and 10mg of ezetimibe, indicated for the treatment of primary hypercholesterolemia. Previously, the market for pitavastatin and ezetimibe combination drugs only offered 2/10mg and 4/10mg dosages, leaving a gap for low-dose options. Barojet Tablet introduces a new 1/10mg low-dose option among pitavastatin-based combination drugs, expanding treatment choices.
SK Chemicals has also strengthened its product portfolio by introducing a low-dose three-drug combination for early-stage hypertension treatment. In April, it launched the low-dose three-drug combination hypertension treatment 'Telamclo Tablet,' which combines 20mg of telmisartan, 2.5mg of amlodipine, and 6.25mg of chlorthalidone, designed with each component at half the standard dosage.
Samjin Pharmaceutical has introduced 'Neutoin Tablet (donepezil hydrochloride) 3mg,' adding a fourth dosage option to its existing 5mg, 10mg, and 23mg lineups for Alzheimer's treatment. This is in line with the recommended gradual dose escalation starting from a low dose.
A representative from Samjin Pharmaceutical stated, "Donepezil-based dementia treatments often see patients discontinuing due to gastrointestinal side effects like nausea and vomiting at the start of treatment, so a gradual dose escalation from a low starting point is recommended." Clinical studies have shown that the group receiving 3mg of donepezil reported a lower incidence of early adverse reactions compared to the 5mg group.
Additionally, JW Pharmaceutical has introduced 'Minoxipaz Tablet 2.5mg,' a hypertension treatment containing minoxidil, allowing for more precise dosage adjustments compared to the existing 5mg tablets. International Pharmaceutical has also launched 'Exduo Tablet 2.5/80mg,' a combination of 2.5mg of amlodipine and 80mg of valsartan. With this addition, International Pharmaceutical now offers a total of four dosage options, broadening prescription choices for patients ranging from early-stage to moderate severity.
Industry experts believe that the focus on low-dose strategies by pharmaceutical companies is driven by changes in patient demographics. As society enters an ultra-aging phase, the number of patients on multiple medications is increasing, and standard dosages can be burdensome for elderly patients with lower body weight or diminished physical function. A pharmaceutical representative noted, "To reduce cases of patients discontinuing medication due to initial side effects, starting with a low dose and monitoring responses is becoming a practical alternative."
According to industry sources on June 7, competition among pharmaceutical companies to offer low-dose options is intensifying, particularly for treatments addressing hyperlipidemia, hypertension, and Alzheimer's disease, which are gaining attention in an aging society.
JW Pharmaceutical has launched a low-dose product for hyperlipidemia treatment, 'Rivarojet 1/10mg,' this month. Rivarojet is the first dual-combination improved new drug in South Korea that combines pitavastatin, a treatment for hyperlipidemia, with ezetimibe. The newly introduced Rivarojet 1/10mg combines 1mg of pitavastatin with 10mg of ezetimibe, expanding the dosage options available to patients while considering their LDL-C levels and treatment goals, alongside the existing 2/10mg and 4/10mg lineups.
The addition of low-dose products allows for more precise dosage adjustments from the start of treatment, thereby broadening patient-specific treatment options. The medical community can now provide more refined prescriptions by considering LDL-C levels, treatment goals, and the risk of side effects.
Earlier, Daewoong Pharmaceutical also released a combination drug for hyperlipidemia, 'Barojet Tablet.' Barojet Tablet is a low-dose combination of 1mg of pitavastatin and 10mg of ezetimibe, indicated for the treatment of primary hypercholesterolemia. Previously, the market for pitavastatin and ezetimibe combination drugs only offered 2/10mg and 4/10mg dosages, leaving a gap for low-dose options. Barojet Tablet introduces a new 1/10mg low-dose option among pitavastatin-based combination drugs, expanding treatment choices.
SK Chemicals has also strengthened its product portfolio by introducing a low-dose three-drug combination for early-stage hypertension treatment. In April, it launched the low-dose three-drug combination hypertension treatment 'Telamclo Tablet,' which combines 20mg of telmisartan, 2.5mg of amlodipine, and 6.25mg of chlorthalidone, designed with each component at half the standard dosage.
Samjin Pharmaceutical has introduced 'Neutoin Tablet (donepezil hydrochloride) 3mg,' adding a fourth dosage option to its existing 5mg, 10mg, and 23mg lineups for Alzheimer's treatment. This is in line with the recommended gradual dose escalation starting from a low dose.
A representative from Samjin Pharmaceutical stated, "Donepezil-based dementia treatments often see patients discontinuing due to gastrointestinal side effects like nausea and vomiting at the start of treatment, so a gradual dose escalation from a low starting point is recommended." Clinical studies have shown that the group receiving 3mg of donepezil reported a lower incidence of early adverse reactions compared to the 5mg group.
Additionally, JW Pharmaceutical has introduced 'Minoxipaz Tablet 2.5mg,' a hypertension treatment containing minoxidil, allowing for more precise dosage adjustments compared to the existing 5mg tablets. International Pharmaceutical has also launched 'Exduo Tablet 2.5/80mg,' a combination of 2.5mg of amlodipine and 80mg of valsartan. With this addition, International Pharmaceutical now offers a total of four dosage options, broadening prescription choices for patients ranging from early-stage to moderate severity.
Industry experts believe that the focus on low-dose strategies by pharmaceutical companies is driven by changes in patient demographics. As society enters an ultra-aging phase, the number of patients on multiple medications is increasing, and standard dosages can be burdensome for elderly patients with lower body weight or diminished physical function. A pharmaceutical representative noted, "To reduce cases of patients discontinuing medication due to initial side effects, starting with a low dose and monitoring responses is becoming a practical alternative."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.